Comparison of Current Staging Systems for Advanced Hepatocellular Carcinoma Not Amendable to Locoregional Therapy As Inclusion Criteria for Clinical Trials

Xing Li,Min Dong,Lin Q,Zhan-Hong Chen,Xiaokun Ma,Yan‐Fang Xing,Xiang-Bo Wan,Ji Wen,Wei Li,Jie Chen,Xiang‐Yuan Wu
DOI: https://doi.org/10.1111/ajco.12050
2012-01-01
Asia-Pacific Journal of Clinical Oncology
Abstract:The prognosis of patients with advanced hepatocellular carcinoma (HCC) is poor and testing drug efficacy in clinical trials is hazardous. This study was aimed to evaluate different prognostic scoring systems for HCC in estimating prognosis (3‐month survival and overall survival (OS)).
What problem does this paper attempt to address?